Developer docs
API playgroundTry for free, no card

Search company profiles

Access Bio

Full company profile

uuid000g9c5

Namestring
Access Bio
Websiteurl
accessbio.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Access Bio is a privately held, small-scale firm (11–50 employees) headquartered in Boyce, United States, described in firmographic data as a consulting group that assists in the development of drug, biological, and medical device products. The available source material does not disclose its product portfolio, pricing model, go-to-market motion, customer segments, or revenue mechanics — the firm's website (accessbio.com) appears as a placeholder/parked domain in the captured content, and no substantive service or technology description is available from primary sources.

The most substantive documented activity is a 2026 acquisition: Access Bio acquired RFTbio, a bio/biological products subsidiary divested by South Korean diversified technology group RFTtech, for approximately 57 billion won as part of RFTtech's reorganization to exit non-core affiliates following the failure of its diversification into bio, semiconductors, and secondary batteries. Following the transaction, Access Bio is described as having retained a partial 18.37% stake position in RFTbio. The combination of a US-headquartered consulting profile with a Korean-won-denominated acquisition raises a potential identity ambiguity that the available sources do not resolve.

No management team, employees, partnerships beyond the RFTbio transaction, certifications, patents, funding rounds, product launches, or technology stack details are disclosed. As a result, the business model, addressable market, and competitive positioning cannot be characterized beyond what is stated above.

Short descriptiontext

Access Bio is a privately held US-based consulting group (11–50 employees, Boyce) supporting drug, biological, and medical device product development, which in 2026 acquired RFTbio from RFTtech for ~57 billion won.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSomerset, United States
HQ citystring
Somerset
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmaceutical consulting, biologics development, medical device consulting, drug development advisory, life sciences consulting
Industry1 code
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical and Life Sciences Consulting
Social media profiles1 record
Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Access Bio is a consulting group that assists clients in the development of drug, biological, and medical device products. The firm provides advisory services rather than manufacturing or selling its own end products. Beyond the consulting description, public sources also reference the company in an acquisition capacity, having acquired RFTbio from RFTtech for approximately 57 billion won.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Based on the limited source data, Access Bio appears to be a company that acquired RFTbio from RFTtech for approximately 57 billion won. No substantive product portfolio, service offerings, or technology platform details are available in the provided sources.

Product and service3 records
1Drug Development Consulting
CategoryPharmaceutical Consulting
Description

Advisory and consulting support to organizations developing pharmaceutical drug products.

2Biological Product Development Consulting
CategoryBiological Products Consulting
Description

Consulting services supporting the development of biological products for client organizations.

3Medical Device Development Consulting
CategoryMedical Device Consulting
Description

Consulting and development support for organizations creating medical device products.

Partnership1 partner
1RFTtech
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Access Bio acquired RFTbio (a subsidiary of RFTtech) for approximately 57 billion won as part of RFTtech's reorganization strategy to shed non-core businesses. RFTtech sold the business to refocus on its core mobile equipment operations. Access Bio retained partial stake of 18.37% in RFTbio following the transaction.

biz.chosun.com
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

South Korea-headquartered global CDMO providing end-to-end biologics development and manufacturing services. Closely relevant peer to the RFTbio subsidiary and to the cross-border nature of Access Bio's recent acquisition from RFTtech.

TypeDirect peer
Description

Global CDMO offering process development, manufacturing, and consulting-adjacent services for biological products. Most directly comparable to the bio products and development services that Access Bio delivers through RFTbio and its consulting arm.

TypeBroad incumbent
Description

Large global CDMO providing development, manufacturing, and consulting-related services across biologics, drugs, and medical devices. Comparable to Access Bio across multiple service lines, though at substantially greater scale.

TypeBroad incumbent
Description

Major CRO and life sciences services provider with biological research, drug development, and consulting offerings. Comparable to Access Bio's drug and biological development consulting focus, though at significantly larger scale.

TypeBroad incumbent
Description

Global leader in CRO and life sciences consulting with deep drug development and biological research capabilities. Directly comparable in service mix to Access Bio's consulting work for drug and biological product development.

TypeBroad incumbent
Description

Asia-headquartered global CRO/CDMO providing drug discovery, development, and manufacturing services. Comparable to Access Bio's consulting + bio products combination, though at much greater scale and broader geographic reach.

TypeDirect peer
Description

Mid-size global CRO providing drug and biological product development consulting and services. Closely comparable in business model and service mix to Access Bio's core consulting practice in drug and biological product development.

TypeDirect peer
Description

Mid-size CRO focused on clinical development services for drugs and biologics. Comparable to Access Bio's development consulting services for drug and biological products, and similarly positioned around specialized sponsor engagements.

TypeDirect peer
Description

Mid-size CRO providing drug and biologics development consulting and clinical services. Comparable in business model, customer base, and service mix to Access Bio's drug and biological product development consulting.

TypeBroad incumbent
Description

Large global CRO providing drug and biological product development services across consulting, clinical, and post-approval. Comparable to Access Bio's consulting services though at meaningfully larger scale and broader geographic coverage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Access Bio

Pharmaceutical and Life Sciences Consultingaccessbio.com

Access Bio is a privately held US-based consulting group (11–50 employees, Boyce) supporting drug, biological, and medical device product development, which in 2026 acquired RFTbio from RFTtech for ~57 billion won.

What Access Bio does

Access Bio is a privately held, small-scale firm (11–50 employees) headquartered in Boyce, United States, described in firmographic data as a consulting group that assists in the development of drug, biological, and medical device products. The available source material does not disclose its product portfolio, pricing model, go-to-market motion, customer segments, or revenue mechanics — the firm's website (accessbio.com) appears as a placeholder/parked domain in the captured content, and no substantive service or technology description is available from primary sources.

The most substantive documented activity is a 2026 acquisition: Access Bio acquired RFTbio, a bio/biological products subsidiary divested by South Korean diversified technology group RFTtech, for approximately 57 billion won as part of RFTtech's reorganization to exit non-core affiliates following the failure of its diversification into bio, semiconductors, and secondary batteries. Following the transaction, Access Bio is described as having retained a partial 18.37% stake position in RFTbio. The combination of a US-headquartered consulting profile with a Korean-won-denominated acquisition raises a potential identity ambiguity that the available sources do not resolve.

No management team, employees, partnerships beyond the RFTbio transaction, certifications, patents, funding rounds, product launches, or technology stack details are disclosed. As a result, the business model, addressable market, and competitive positioning cannot be characterized beyond what is stated above.

Access Bio firmographics

Firmographics
Name
Access Bio
Website
https://accessbio.com
Company type
Private
Operating status
Operating
Headcount range
51–100 employees
Short description
Access Bio is a privately held US-based consulting group (11–50 employees, Boyce) supporting drug, biological, and medical device product development, which in 2026 acquired RFTbio from RFTtech for ~57 billion won.
Ownership category
akta.pro rank

Access Bio industry classification

Industry
Product category
Pharmaceutical and Life Sciences Consulting
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)

Keywords

  • Pharmaceutical consulting
  • Biologics development
  • Medical device consulting
  • Drug development advisory
  • Life sciences consulting

Where Access Bio is headquartered

Location

Headquarters

HQ city
Somerset
HQ country
United States
HQ region
North America

Markets served

Access Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Access Bio product offering

Product offering

Core offering

Access Bio is a consulting group that assists clients in the development of drug, biological, and medical device products. The firm provides advisory services rather than manufacturing or selling its own end products. Beyond the consulting description, public sources also reference the company in an acquisition capacity, having acquired RFTbio from RFTtech for approximately 57 billion won.

Product overview

Based on the limited source data, Access Bio appears to be a company that acquired RFTbio from RFTtech for approximately 57 billion won. No substantive product portfolio, service offerings, or technology platform details are available in the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Development Consulting Advisory and consulting support to organizations developing pharmaceutical drug products.
  • Biological Product Development Consulting Consulting services supporting the development of biological products for client organizations.
  • Medical Device Development Consulting Consulting and development support for organizations creating medical device products.

Companies that use Access Bio

Customer profile

Ideal customer profiles1 record

Access Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Access Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RFTtechcoreStrategic or Co-development PartnerAccess Bio acquired RFTbio (a subsidiary of RFTtech) for approximately 57 billion won as part of RFTtech's reorganization strategy to shed non-core businesses. RFTtech sold the business to refocus on its core mobile equipment operations. Access Bio retained partial stake of 18.37% in RFTbio following the transaction.

Recent moves1 record

Expansion highlights2 records

Access Bio competitors and assessment

Company assessment

Broad incumbents

  • Samsung Biologics: South Korea-headquartered global CDMO providing end-to-end biologics development and manufacturing services. Closely relevant peer to the RFTbio subsidiary and to the cross-border nature of Access Bio's recent acquisition from RFTtech.
  • Catalent: Large global CDMO providing development, manufacturing, and consulting-related services across biologics, drugs, and medical devices. Comparable to Access Bio across multiple service lines, though at substantially greater scale.
  • Charles River Laboratories: Major CRO and life sciences services provider with biological research, drug development, and consulting offerings. Comparable to Access Bio's drug and biological development consulting focus, though at significantly larger scale.
  • IQVIA Holdings: Global leader in CRO and life sciences consulting with deep drug development and biological research capabilities. Directly comparable in service mix to Access Bio's consulting work for drug and biological product development.
  • WuXi AppTec: Asia-headquartered global CRO/CDMO providing drug discovery, development, and manufacturing services. Comparable to Access Bio's consulting + bio products combination, though at much greater scale and broader geographic reach.
  • ICON plc: Large global CRO providing drug and biological product development services across consulting, clinical, and post-approval. Comparable to Access Bio's consulting services though at meaningfully larger scale and broader geographic coverage.

Direct peers

  • AGC Biologics: Global CDMO offering process development, manufacturing, and consulting-adjacent services for biological products. Most directly comparable to the bio products and development services that Access Bio delivers through RFTbio and its consulting arm.
  • Parexel International: Mid-size global CRO providing drug and biological product development consulting and services. Closely comparable in business model and service mix to Access Bio's core consulting practice in drug and biological product development.
  • Medpace: Mid-size CRO focused on clinical development services for drugs and biologics. Comparable to Access Bio's development consulting services for drug and biological products, and similarly positioned around specialized sponsor engagements.
  • Syneos Health: Mid-size CRO providing drug and biologics development consulting and clinical services. Comparable in business model, customer base, and service mix to Access Bio's drug and biological product development consulting.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

Access Bio social profiles

Digital presence

Access Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Access Bio leadership team

Management profile

Number of profiles

Access Bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Access Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Access Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Access Bio

What does Access Bio do?

Access Bio is a consulting group that assists clients in the development of drug, biological, and medical device products. The firm provides advisory services rather than manufacturing or selling its own end products. Beyond the consulting description, public sources also reference the company in an acquisition capacity, having acquired RFTbio from RFTtech for approximately 57 billion won.

Is Access Bio a public or private company?

Access Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Access Bio founded?

Access Bio was founded in -1. It employs 51 to 100 people.

Where is Access Bio based?

Access Bio is headquartered in Somerset, United States, in the North America region.

Who are Access Bio's main competitors?

Broad incumbents on record are Samsung Biologics, Catalent, Charles River Laboratories, IQVIA Holdings, WuXi AppTec and ICON plc. Direct peers are AGC Biologics, Parexel International, Medpace and Syneos Health.

Does Access Bio have an API?

No public API is recorded for Access Bio.

What industry is Access Bio in?

Access Bio's product category is Pharmaceutical and Life Sciences Consulting. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAccess Bio Signs USD 3.73 Million Contract to Supply Flu, COVID-19 Home Tests to P&G SubsidiaryAccess Bio signed a KRW 4.97 billion supply contract with Procter & Gamble Manufacturing on October 20, 2026, for flu and COVID-19 home tests in the US. The contract value represents 15.89% of 2025 consolidated revenue, with supply running from October 15, 2026, through October 14, 2027.ChosunbizRFTtech shifts from M&A to downsizing, sheds noncore affiliates in KoreaRFTtech, a South Korean company that expanded through aggressive M&A, is reorganizing its affiliates by selling off non-core businesses after its diversification strategy into bio, semiconductors, and secondary batteries failed to improve results. The company sold RFTbio to Access Bio for approximately 57 billion won and handed over the largest shareholder position in HANJOO ART to P&A Investment Partnership through a 3.5 billion won paid-in capital increase, while retaining partial stakes of 18.37% and 18.93% respectively. The moves follow the collapse of a planned management rights transfer to Pound Equity Partners and Busan Equity Partners, with industry analysis viewing this as an effort to shed underperforming affiliates and refocus on its core mobile equipment business.GlobeNewswireADG and Maddox Defense Partner with Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics AgencyADG, with Maddox Defense and Access Bio, won a $410M IDIQ contract to deliver US-made COVID test kits to the Defense Logistics Agency. Access Bio has already received and commenced deliveries under the first $205M order, with ADG expecting $19M in revenue over six months and up to $38M over the contract's lifetime.GlobeNewswireAirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics AgencyThe Defense Logistics Agency awarded an IDIQ contract up to $410M to Access Bio, supported by AirBoss Defense Group and Maddox Defense, for US-made COVID test kits. Access Bio has already received and commenced deliveries on the first $205M order, with AirBoss expecting $19M in revenue over six months and up to $38M over the contract's lifetime.GlobeNewswireGlobal WholeHealth Partners Corp (GWHP-OTC) to Announce that Global is Now Selling Access Bio Antigen TestGlobal WholeHealth Partners Corp announced it is now selling the Access Bio antigen test for COVID-19. The company states the U.S. needs 193 million tests per month, and its test can deliver results in minutes. It also notes a third surge threatens the U.S. and its EUA filing is pending.